[{"orgOrder":0,"company":"Azitra","sponsor":"Leaps by Bayer","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Series B Financing","leadProduct":"ATR-01","moa":"Acetoacetyl-CoA thiolase (ACAT1)","graph1":"Dermatology","graph2":"Preclinical","graph3":"Azitra","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Azitra \/ Leaps by Bayer","highestDevelopmentStatusID":"4","companyTruncated":"Azitra \/ Leaps by Bayer"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"PN-881","moa":"IL-17","graph1":"Dermatology","graph2":"Preclinical","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Protagonist Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"JT-09","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Titan Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Titan Pharmaceuticals Inc","sponsor":"MUSC Foundation for Research Development","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"TP-2021","moa":"Kappa opioid receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Titan Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development","highestDevelopmentStatusID":"4","companyTruncated":"Titan Pharmaceuticals Inc \/ MUSC Foundation for Research Development"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Expanded Collaboration","leadProduct":"HT-003","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Cornell Medicine \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"VNLG 152","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Isoprene Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Licensing Agreement","leadProduct":"VNLG 152","moa":"MNK1\/MNK2","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Isoprene Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Isoprene Pharmaceuticals"},{"orgOrder":0,"company":"Camargo Pharmaceutical","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Aprepitant","moa":"Neurokinin 1 receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Camargo Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Camargo Pharmaceutical \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Camargo Pharmaceutical \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Aditxt","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"ADI-100","moa":"Pro-inflammatory cytokine","graph1":"Dermatology","graph2":"Preclinical","graph3":"Aditxt","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aditxt \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Aditxt \/ Undisclosed"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"George Washington University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ George Washington University","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ George Washington University"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"WEG232","moa":"Substance P receptor","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MiMedx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Purion Processed Dehydrated Human Amnion\/Chorion Membrane","moa":"TGF-beta-1","graph1":"Dermatology","graph2":"Preclinical","graph3":"MiMedx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MiMedx \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MiMedx \/ Undisclosed"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"BD9","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Biolojic Design","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"4","companyTruncated":"Biolojic Design \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"FibroBiologics","sponsor":"Yorkville","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Financing","leadProduct":"CYPS317","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"FibroBiologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"FibroBiologics \/ Yorkville","highestDevelopmentStatusID":"4","companyTruncated":"FibroBiologics \/ Yorkville"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Genoa Ventures","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Series A Financing","leadProduct":"Human Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Genoa Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Genoa Ventures"},{"orgOrder":0,"company":"KBI Biopharma","sponsor":"Infinimmune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Collaboration","leadProduct":"IFX-101","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"KBI Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KBI Biopharma \/ Infinimmune","highestDevelopmentStatusID":"4","companyTruncated":"KBI Biopharma \/ Infinimmune"},{"orgOrder":0,"company":"UC San Diego","sponsor":"MatriSys Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Licensing Agreement","leadProduct":"MSB-3163","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"UC San Diego","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UC San Diego \/ MatriSys Bioscience","highestDevelopmentStatusID":"4","companyTruncated":"UC San Diego \/ MatriSys Bioscience"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Retinamide","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"TLC-1235","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OrsoBio \/ Yale University","highestDevelopmentStatusID":"4","companyTruncated":"OrsoBio \/ Yale University"},{"orgOrder":0,"company":"Exicure","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Undisclosed","year":"2022","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Exicure","amount2":1.05,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":1.05,"dosageForm":"Undisclosed","sponsorNew":"Exicure \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Exicure \/ AbbVie Inc"},{"orgOrder":0,"company":"Alys Pharmaceuticals","sponsor":"Medicxi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Alys Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.10000000000000001,"dosageForm":"Gel","sponsorNew":"Alys Pharmaceuticals \/ Medicxi","highestDevelopmentStatusID":"4","companyTruncated":"Alys Pharmaceuticals \/ Medicxi"},{"orgOrder":0,"company":"Weill Cornell Medicine","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Weill Cornell Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Weill Cornell Medicine \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":2.1499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Kymera Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Stemson Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Stemson Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stemson Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Stemson Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Evommune","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Evommune","highestDevelopmentStatusID":"4","companyTruncated":"Eli Lilly \/ Evommune"},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"23andMe \/ Almirall","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Nimble Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Nimble Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"4","companyTruncated":"Nimble Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Premji Invest","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Enveda Bioscience","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Premji Invest","highestDevelopmentStatusID":"4","companyTruncated":"Enveda Bioscience \/ Premji Invest"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hoth Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Rubedo Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Rubedo Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rubedo Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Rubedo Life Sciences \/ Undisclosed"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
